Quantum BioPharma (STU:0K91) EBIT : €-10.14 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma EBIT?

Quantum BioPharma's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was €-3.61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was €-10.14 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Quantum BioPharma's annualized ROC % for the quarter that ended in Sep. 2024 was -193.48%. Quantum BioPharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -15,116.23%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Quantum BioPharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -295.06%.

Quantum BioPharma EBIT Historical Data

The historical data trend for Quantum BioPharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum BioPharma EBIT Chart

Quantum BioPharma Annual Data

Trend

Aug15

Aug16

Aug17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-30.53

-23.19

-29.97

-25.16

-16.72

Quantum BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															-2.62	-1.52	-1.91	-3.11	-3.61

Competitive Comparison of Quantum BioPharma's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Quantum BioPharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quantum BioPharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Quantum BioPharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Quantum BioPharma's EV-to-EBIT falls into.

Quantum BioPharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.14 Mil.

Quantum BioPharma (STU:0K91) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Quantum BioPharma's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-14.68 * ( 1 - 0% )	/	( (6.965	+	8.21)	/ 2 )
=	-14.68	/	7.5875
=	-193.48 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	14.164	-	4.106	-	( 3.093	-	max(0, 4.687	-	9.31	+	3.093	))
=	6.965

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	17.143	-	2.981	-	( 5.952	-	max(0, 3.317	-	12.473	+	5.952	))
=	8.21

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Quantum BioPharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-14.436	/	( ( (0.068 + max(-3.986, 0))	+	(0.123 + max(-2.846, 0)) )	/	2 )
=	-14.436	/	( ( 0.068	+	0.123 )	/	2 )
=	-14.436	/	0.0955
=	-15,116.23 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.12)	-	(4.106	+	0	+	8.8817841970013E-16)
=	-3.986

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.135)	-	(2.981	+	0	+	4.4408920985006E-16)
=	-2.846

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Quantum BioPharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-10.144	/	3.438
	=	-295.06 %

Quantum BioPharma EBIT Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantum BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Quantum BioPharma Ltd (STU:0K91) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

QNTM:USA QNTM:Canada

Address

199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9

Website

https://www.fsdpharma.com

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

Quantum BioPharma Headlines

No Headlines